COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead

Gentile, Francesco; Aimo, Alberto; Forfori, Francesco; Catapano, Giosué; Clemente, Alberto; Cademartiri, Filippo; Emdin, Michele; Giannoni, Alberto

doi:10.1177/2047487320932695

Cited by 88 publications

(83 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another follow up study 21 which studied the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery enrolled 55 patients and found different degrees of radiological abnormalities were detected in 39 patients. Blood Urea nitrogen concentration at admission was associated with the presence of CT abnormalities.…”

Section: Mechanism Of Post Covid Pulmonary Fibrosismentioning

confidence: 99%

Post covid 19 pulmonary fibrosis. Is it real threat?

Kumar

Sharma

Kumar

2021

Indian Journal of Tuberculosis

131

108

View full text Add to dashboard Cite

Section: Mechanism Of Post Covid Pulmonary Fibrosismentioning

confidence: 99%

Post covid 19 pulmonary fibrosis. Is it real threat?

Kumar

Sharma

Kumar

2021

Indian Journal of Tuberculosis

131

108

View full text Add to dashboard Cite

“…Already there is clinical and CT evidence that patients with COVID-19 pneumonia can progress to pulmonary fibrosis. (15)(16)(17)(18) Given the many millions of infected patients worldwide even if the long term risk is small there could be significant numbers of patients who progress to pulmonary fibrosis. This has led to several proposals for consideration of antifibrotic therapies to prevent or to treat COVID -19 pneumonia.…”

Section: Introductionmentioning

confidence: 99%

Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID‐19 pneumonia in Wuhan, China

Wang

et al. 2020

Histopathology

View full text Add to dashboard Cite

Aims: Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has been deemed as a global pandemic by World Health Organization. While diffuse alveolar damage (DAD) is recognized to be the primary manifestation COVID-19 pneumonia, there has been little emphasis on the progression to the fibrosing phase of DAD. This topic is of great interest due to growing concerns regarding the potential long-term complications in prolonged survivors. Methods: Here we report a detailed histopathologic study of thirty autopsy cases with COVID-19 virus infection, based on minimally invasive autopsies performed between February to March, 2020. Results: The mean age was 69 years, with twenty (67%) males and 10 (33%) females and frequent (70.0%) underlying comorbidities. The duration of illness ranged from 16 to 82 (median=42) days. Histologically, the most common manifestation was diffuse alveolar damage (DAD) in 28 (93.3%) cases which showed predominantly acute (32%), organizing (25%), and/or fibrosing (43%) patterns. Patients with fibrosing DAD were one decade younger (p=0.034) and they had a longer duration of illness (p=0.033), hospitalization (p=0.037) and mechanical ventilation (p=0.014) compared to those with acute DAD. Patients with organizing DAD had a longer duration of illness (p=0.032) and hospitalization (p=0.023) compared to those with acute DAD. Conclusions: COVID-19 pneumonia patients who develop DAD can progress to the fibrosing pattern. While we observed fibrosing DAD in fatal cases, whether surviving patients are at risk for developing pulmonary fibrosis and the frequency of this complication will require further clinical and radiologic follow-up studies.

show abstract

“…While acute pulmonary embolism is not a rare finding in patients with COVID-19 pneumonia [ 1 , 2 ], the prevalence of pulmonary fibrosis remains unclear [ 3 , 4 , 5 ]. During previous coronavirus outbreaks, pulmonary fibrosis was reported in up to one-third of patients [ 3 , 4 , 5 ]. Therefore, given the worldwide spread of COVID-19, a considerable number of cases with associated pulmonary fibrosis are expected.…”

mentioning

confidence: 99%

COVID-19 Pneumonia: Three Thoracic Complications in the Same Patient

et al. 2020

View full text Add to dashboard Cite

The most dreaded thoracic complications in patients with coronavirus disease 2019 (COVID-19) are acute pulmonary embolism and pulmonary fibrosis. Both the complications are associated with an increased risk of morbidity and mortality. While acute pulmonary embolism is not a rare finding in patients with COVID-19 pneumonia, the prevalence of pulmonary fibrosis remains unclear. Spontaneous pneumothorax is another possible complication in COVID-19 pneumonia, although its observation is rather uncommon. Herein, we present interesting computed tomography images of the first case of COVID-19 pneumonia that initially developed acute pulmonary embolism and subsequently showed progression toward pulmonary fibrosis and spontaneous pneumothorax.

show abstract

COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead

Cited by 88 publications

References 19 publications

Post covid 19 pulmonary fibrosis. Is it real threat?

Post covid 19 pulmonary fibrosis. Is it real threat?

Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID‐19 pneumonia in Wuhan, China

COVID-19 Pneumonia: Three Thoracic Complications in the Same Patient

Contact Info

Product

Resources

About